FDA approves HPV immunotherapy for RRP

In a study of 32 adults with recurrent respiratory papillomatosis, treatment reduced the need for repeated surgery.

1

The FDA granted accelerated approval to Voceryq to reduce surgical papilloma excisions in adults with recurrent respiratory papillomatosis.
2

Voceryq is the first plasmid DNA-based immunotherapy approved in the United States and targets HPV types 6 and 11.
3

Approval was supported by an open-label, single-arm phase 1/2 study of 32 adults, without a concurrent control group.
4

Among 26 patients who had required at least 3 surgeries before treatment, 7 had no excisions during the following 12 months.
5

The FDA label recommends 4 intramuscular doses 3 weeks apart after surgical removal of visible papillomas, administered by a trained health care professional.